Edition:
India

St. Jude Medical Inc (STJ.N)

STJ.N on New York Stock Exchange

75.85USD
1:32am IST
Change (% chg)

$-0.45 (-0.59%)
Prev Close
$76.30
Open
$76.07
Day's High
$76.28
Day's Low
$75.71
Volume
1,389,847
Avg. Vol
687,852
52-wk High
$80.35
52-wk Low
$48.83

STJ.N

Chart for STJ.N

About

St. Jude Medical, Inc. is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement... (more)

Overall

Beta: 1.26
Market Cap(Mil.): $21,643.99
Shares Outstanding(Mil.): 283.67
Dividend: 0.31
Yield (%): 1.63

Financials

Search Stocks

Abbott deal for St. Jude spurs company split talk

NEW YORK When Abbott Laboratories said on Thursday it would buy heart device company St. Jude Medical Inc for $25 billion, it set off a flurry of Wall Street speculation over whether Abbott Chief Executive Miles White is laying groundwork to split the company yet again.

29 Apr 2016

Abbott deal for St. Jude spurs company split talk

NEW YORK, April 28 When Abbott Laboratories said on Thursday it would buy heart device company St. Jude Medical Inc for $25 billion, it set off a flurry of Wall Street speculation over whether Abbott Chief Executive Miles White is laying groundwork to split the company yet again.

29 Apr 2016

Fitch Places St. Jude Medical on Rating Watch Negative

(The following statement was released by the rating agency) CHICAGO, April 28 (Fitch) Fitch Ratings has placed St. Jude Medical, Inc. (STJ, St. Jude) on Rating Watch Negative. The rating action follows Abbott Laboratories' (ABT, Abbott) announcement of its intention to acquire St. Jude. Fitch will resolve the Rating Watch as more details regarding the transactions become available. However, given the currently available information and assuming Abbott acquires both Alere and St. Jude, Fitch

29 Apr 2016

BRIEF-S&P- Abbott Laboratories ratings remain on creditwatch negative on planned acquisition of St. Jude

* Abbott Laboratories ratings remain on creditwatch negative on planned acquisition of St. Jude Medical Source text: (http://bit.ly/21hkyCp) (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)

28 Apr 2016

BRIEF-Abbott to acquire St. Jude medical

* Transaction expected to be accretive to abbott's adjusted earnings per share(1) in first full year after closing and increasing thereafter

28 Apr 2016

Abbott to acquire St. Jude Medical for $25 bln

April 28 Abbott Laboratories said it agreed to buy medical device maker St. Jude Medical Inc for $25 billion.

28 Apr 2016

Heart failure devices pump up St. Jude's profit, revenue

St. Jude Medical Inc reported better-than-expected quarterly results helped by strong heart failure device sales and said it was making progress in getting its pacemaker and defibrillator business back on track.

20 Apr 2016

REFILE-UPDATE 2-Heart failure devices pump up St. Jude's profit, revenue

April 20 St. Jude Medical Inc reported better-than-expected quarterly results helped by strong heart failure device sales and said it was making progress in getting its pacemaker and defibrillator business back on track.

20 Apr 2016

CORRECTED-Medical device maker St. Jude reports 7.6 pct rise in revenue

April 20 St. Jude Medical Inc reported a 7.6 percent rise in quarterly revenue, helped by higher sales in its heart failure and neuromodulation businesses.

20 Apr 2016

BRIEF-St. Jude Medical reports Q1 adj share of $0.90

* Q1 earnings per share view $0.88 -- Thomson Reuters I/B/E/S

20 Apr 2016

Earnings vs. Estimates

Search Stocks